- Home
- VCIG vs QLGN Comparison
VCIG vs QLGN Comparison
Compare VCIG & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCIG
- QLGN
- Stock Information
- Founded
- VCIG 2013
- QLGN 1996
- Country
- VCIG Malaysia
- QLGN United States
- Employees
- VCIG N/A
- QLGN N/A
- Industry
- VCIG Diversified Commercial Services
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- VCIG Consumer Discretionary
- QLGN Health Care
- Exchange
- VCIG Nasdaq
- QLGN Nasdaq
- Market Cap
- VCIG 5.3M
- QLGN 4.7M
- IPO Year
- VCIG 2023
- QLGN N/A
- Fundamental
- Price
- VCIG $1.23
- QLGN $2.80
- Analyst Decision
- VCIG
- QLGN
- Analyst Count
- VCIG 0
- QLGN 0
- Target Price
- VCIG N/A
- QLGN N/A
- AVG Volume (30 Days)
- VCIG 6.4M
- QLGN 2.5M
- Earning Date
- VCIG 08-18-2025
- QLGN 07-21-2025
- Dividend Yield
- VCIG N/A
- QLGN N/A
- EPS Growth
- VCIG N/A
- QLGN N/A
- EPS
- VCIG 54.73
- QLGN N/A
- Revenue
- VCIG $27,819,290.00
- QLGN N/A
- Revenue This Year
- VCIG N/A
- QLGN N/A
- Revenue Next Year
- VCIG N/A
- QLGN N/A
- P/E Ratio
- VCIG $0.02
- QLGN N/A
- Revenue Growth
- VCIG 36.99
- QLGN N/A
- 52 Week Low
- VCIG $0.88
- QLGN $2.74
- 52 Week High
- VCIG $519.20
- QLGN $13.50
- Technical
- Relative Strength Index (RSI)
- VCIG 38.86
- QLGN 35.34
- Support Level
- VCIG $0.90
- QLGN $2.77
- Resistance Level
- VCIG $1.07
- QLGN $3.29
- Average True Range (ATR)
- VCIG 0.17
- QLGN 0.53
- MACD
- VCIG 0.06
- QLGN -0.06
- Stochastic Oscillator
- VCIG 43.75
- QLGN 1.65
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.